STAAR Surgical (NASDAQ:STAA) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 16.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 189,481 shares of the medical instruments supplier’s stock after buying an additional 27,143 shares during the period. Victory Capital Management Inc. owned approximately 0.38% of STAAR Surgical worth $7,039,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Arcadia Investment Management Corp MI bought a new stake in STAAR Surgical during the third quarter worth approximately $37,000. Canada Pension Plan Investment Board purchased a new position in STAAR Surgical during the second quarter valued at approximately $129,000. Van ECK Associates Corp raised its holdings in shares of STAAR Surgical by 12.7% during the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock worth $129,000 after acquiring an additional 393 shares in the last quarter. Larson Financial Group LLC bought a new position in STAAR Surgical during the second quarter valued at approximately $130,000. Finally, nVerses Capital LLC raised its holdings in STAAR Surgical by 78.3% during the third quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier’s stock valued at $152,000 after buying an additional 1,800 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors.

STAAR Surgical Stock Up 1.2 %

NASDAQ:STAA opened at $26.63 on Friday. STAAR Surgical has a twelve month low of $25.88 and a twelve month high of $52.68. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 60.52 and a beta of 0.61. The stock’s 50 day moving average price is $30.99 and its two-hundred day moving average price is $36.81.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a report on Thursday, October 31st. Stifel Nicolaus decreased their price target on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, August 26th. Finally, Canaccord Genuity Group cut their target price on shares of STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $43.33.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.